Predictors of thrombotic events in patients with post-COVID condition
S. S. Petrikov,
A. A. Ivannikov,
A. I. Tarzimanova,
A. Yu. Bulanov,
I. P. Mikhaylov,
L. A. Dandanyan,
H. G. Alidzhanova https://doi.org/10.33667/2078-5631-2022-17-7-14
Abstract
Introduction. COVID-19 induces a procoagulant state, which can lead to various thrombotic and thromboembolic complications, however, there are just a few studies and papers devoted to COVID-19 long-term thrombotic complications.
Purpose. To assess COVID-19, that was experienced more than 12 weeks ago, as a risk factor for developing arterial and venous thrombotic events in the setting of Vascular Surgery Department of N. V. Sklifosovsky Research Institute for Emergency Medicine.
Materials and Methods. The study included 145 patients, 83 (57.2 %) were male, 62 (42.8 %) were female. Mean age of men was 65.0 [57.0; 72.0] years, mean age of women – 73.5 [62.3; 82.0] years (p = 0.003); 84 patients (57.9 %) were older than 65 years. 19 patients (13.1 %) were diagnosed with pulmonary embolism, 79 (54.5 %) with arterial thrombosis of mixed genesis, 46 (31.7 %) with venous thrombosis, 18 (12.4 %) were diagnosed with thrombophlebitis. In the group of patients with history of COVID-19 12 or more weeks ago 45 (58.44 %) were taking antithrombotic medications.
The most common comorbidities were arterial hypertension (83.44 %), chronic kidney disease (82.06 %) and coronary artery disease (62.06 %).
Results. A statistically significant mean correlation was found between anti-SARS-CoV-2 IgG and hemoglobin (r = –0,326; p = 0,006) and between anti-SARS-CoV-2 IgG and glomerular filtration rate (r = –0,300; p = 0,010). COVID-19, that was experienced 12 and more weeks ago, is not a statistically significant predictor of arterial (OR = 1.01; 95 % CI: 0.552–1.940; p = 0.987) and venous (OR = 0.733; 95 % CI: 0.364–1.479, p = 0.386) thrombotic events. Main risk factors for developing thrombotic events in those patients were comorbidities and predisposing factors: arterial hypertension (OR = 6.923; 95 % CI: 1.3842–34.630; p = 0.018), coronary artery disease (OR = 9.867; 95 % CI: 3.1272–31.1310; p < 0.001), atrial fibrillation (OR = 3.875; 95 % CI: 1.141–13.170; p = 0.030), and smoking (OR = 5.855; 95 % CI: 1.201–28.550; p = 0.029).
Conclusion. Alone, COVID-19, that was experienced more than 12 weeks ago, as not a strong predictor of developing arterial and venous thrombotic events. However, in patients with comorbidities, such as arterial hypertension, coronary artery disease and atrial fibrillation, and in presence of predisposing modifying lifestyle factors, such as smoking, there is a statistically significant risk of various thrombotic events.
About the Authors
S. S. Petrikov
Research Institute for Emergency Medicine n. a. N. V. Sklifosovsky; RAS
Russian Federation
Russian Federation
Sergey S. Petrikov , DM Sci (habil.), academician, director
Moscow
A. A. Ivannikov
Research Institute for Emergency Medicine n. a. N. V. Sklifosovsky; First Moscow State Medical University n. a. I. M. Sechenov
Russian Federation
Russian Federation
Aleksandr A. Ivannikov , lecturer, postgraduate student
Training Center
Institute of Clinical Medicine n. a. N. V. Sklifosovsky
Dept of Faculty Therapy No. 2
Moscow
A. I. Tarzimanova
First Moscow State Medical University n. a. I. M. Sechenov
Russian Federation
Russian Federation
Aida I. Tarzimanova , DM Sci (habil.), professor
Institute of Clinical Medicine n. a. N. V. Sklifosovsky
Dept of Faculty Therapy No. 2
Moscow
A. Yu. Bulanov
Dept of Health of the City of Moscow
Russian Federation
Russian Federation
Andrey Yu. Bulanov, DM Sci (habil.), head of Dept, chief freelance transfusiologist
Research Institute for Emergency Medicine n. a. N. V. Sklifosovsky
Mobile Resuscitation Hematological Brigade
Moscow
I. P. Mikhaylov
Research Institute for Emergency Medicine n. a. N. V. Sklifosovsky
Russian Federation
Russian Federation
Igor P. Mikhailov, DM Sci (habil.), professor, scientific supervisor
Dept of Vascular Surgery
Moscow
L. A. Dandanyan
Research Institute for Emergency Medicine n. a. N. V. Sklifosovsky
Russian Federation
Russian Federation
Lilit A. Dandanyan, clinical resident in cardiolog
Moscow
H. G. Alidzhanova
Research Institute for Emergency Medicine n. a. N. V. Sklifosovsky
Russian Federation
Russian Federation
Khafiza G. Alijanova, DM Sci (habil.), senior lecturer
Training Centre
Moscow
References
1. Hanff T. C., Mohareb A. M., Giri J., Cohen J. B., Chirinos J. A. Thrombosis in COVID-19. Am J Hematol. 2020; 95 (12): 1578–1589. https://doi.org/10.1002/ajh.25982 PMID: 32857878
2. Page E. M., Ariëns R. A. S. Mechanisms of thrombosis and cardiovascular complications in COVID-19. Thrombosis Research. 2021; 200: 1–8. https://doi.org/10.1016/j.thromres.2021.01.005 PMID: 33493983.
3. Helms J., Tacquard C., Severac F., Leonard-LorantI, Ohana M., Delabranche X., et al. High risk of thrombosis in patients with severe SARS-CoV-2 infection: A multicenter prospective cohort study. Intensive Care Med. 2020; 46 (6): 1089–1098. https://doi.org/10.1007/s00134–020–06062-x. PMID: 32367170.
4. Cattaneo M., Bertinato E. M., Birocchi S, Brizio C, Malavolta D., Manzoni M., et al. Pulmonary embolism or pulmonary thrombosis in COVID-19? Is the recommendation to use high-dose heparin for thromboprophylaxis justified? Thromb Haemost. 2020; 120 (8): 1230–1232. https://doi.org/10.1055/s-0040–1712097. PMID: 32349132.
5. Rashidi F., Barco S., Kamangar F., Heresi G. A., Emadi A., Kaymaz C., et al. Incidence of symptomatic venous thromboembolism following hospitalization for coronavirus disease 2019: prospective results from a multi-center study. Thromb Res. 2021; 198: 135–138. https://doi.org/10.1016/j.thromres.2020.12.001. PMID: 33338976.
6. Vlachou M., Drebes A., Candilio L., Weeraman D., Mir N., Murch N., et al. Pulmonary thrombosis in Covid-19: before, during and after hospital admission. J Thromb Thrombolysis. 2021; 51 (4): 978–984. https://doi.org/10.1007/s11239–020–02370–7. PMID: 33386559.
7. Roberts L. N., Whyte M. B., Georgiou L., Giron G., Czuprynska J., Rea C., et al. Postdischarge venous thromboembolism following hospital admission with COVID-19. Blood. 2020; 136 (11): 1347–1350. https://doi.org/10.1182/blood.2020008086. PMID: 32746455.
8. Zuin M., Rigatelli G., Zuliani G., Roncon L. The risk of thrombosis after acute-COVID-19 infection. QJM. 2021; 114 (9): 619–620. https://doi.org/10.1093/qjmed/hcab054. PMID: 33720351.
9. Spyropoulos A. C., Ageno W., Albers G. W., Elliott C. G., Halperin J. L., Hiatt W. R., et al. Post-discharge prophylaxis with rivaroxaban reduces fatal and major thrombo-embolic events in medically ill patients. J Am Coll Cardiol. 2020; 75 (25): 3140–3147. https://doi.org/10.1016/j.jacc.2020.04.071. PMID: 32586587.
10. Giannis D., Allen S. L., Tsang J., Flint S., Pinhasov T., Williams S., et al. Post-discharge thromboembolic outcomes and mortality of hospitalized COVID-19 patients: The CORE-19 registry. Blood. 2021; 137 (20): 2838–2847. https://doi.org/10.1182/blood.2020010529
11. Sepulveda C., Palomo I., Fuentes E. Mechanisms of endothelial dysfunction during aging: Predisposition to thrombosis. Mech Ageing Dev. 2017; 164: 91–99. https://doi.org/10.1016/j.mad.2017.04.011. PMID: 28477984.
12. Taneri P. E., Gómez-Ochoa S. A., Llanaj E., Raguindin P. F., Rojas L. Z., Roa-Díaz, et al. Anemia and iron metabolism in COVID-19: A systematic review and meta-analysis. Eur J Epidemiol. 2020; 35 (8): 763–773. https://doi.org/10.1007/s10654–020–00678–5. PMID: 32816244.
13. Sonnweber T., Boehm A., Sahanic S., Pizzini A., Aichner M., Sonnweber B., et al. Persisting alterations of iron homeostasis in COVID-19 are associated with non-resolving lung pathologies and poor patients’ performance: A prospective observational cohort study. Respir Res. 2020; 21 (1): 276.https://doi.org/10.1186/s12931–020–01546–2. PMID: 33087116.
14. Weiss G., Ganz T., Goodnough L. T. Anemia of inflammation. Blood. 2019; 133 (1): 40–50. https://doi.org/10.1182/blood-2018–06–856500. PMID: 30401705.
15. Orino K., Lehman L., Tsuji Y., Ayaki H., Torti S. V., Torti F. M. Ferritin and the response to oxidative stress. Biochem J. 2001; 357 (Pt1): 241–247. https://doi.org/10.1042/bj3570241. PMID: 11415455.
16. Cavezzi A., Troiani E., Corrao S. COVID-19: hemoglobin, iron, and hypoxia beyond inflammation. A narrative review. Clin Pract. 2020; 10 (2): 1271. https://doi.org/10.4081/cp.2020.1271. PMID: 32509258.
17. Lazarian G., Quinquenel A., Bellal M., Siavellis J., Jacquy C., Re D., et al. Autoimmune haemolyticanaemia associated with COVID-19 infection. Br J Haematol. 2020; 190 (1): 29–31. https://doi.org/10.1111/bjh.16794. PMID: 32374906.
18. Liu W., Li H. COVID-19: Attacks the 1-beta chain of hemoglobin and captures the porphyrin to inhibit human heme metabolism. Chem Rxiv. 2020. https://doi.org/10.26434/chemrxiv.11938173.v9
19. Lechuga G. C., Souza-Silva F., Sacramento C. Q., Trugilho M. R. O., Valente R. H., Napoleão-Pêgo P., et al. SARS-CoV-2 proteins bind to hemoglobin and its metabolites. Int J Mol Sci. 2021; 22 (16): 9035. https://doi.org/10.3390/ijms22169035. PMID: 34445741.
20. Djaldetti M., Blay A., Bergman M., Salman H., Bessler H. Pure red cell aplasia – a rare disease with multiple causes. Biomed Pharmacother. 2003; 57 (8): 326–332. https://doi.org/10.1016/j.biopha.2003.08.001. PMID: 14568226.
21. Yamazaki S., Naito E., Sekiya R., Yogi S., Komiyama K., Miyakawa Y., et al. Pure red cell aplasia accompanied by COVID-19 successfully treated using cyclosporine. J Infect Chemothe. 2021. https://doi.org/10.1016/j.jiac.2021.10.018. PMID: 34772624.
22. Hanna R. M., Streja E., Kalantar-Zadeh K. Burden of anemia in chronic kidney disease: beyond erythropoietin. Adv Ther. 2021; 38 (1): 52–75. https://doi.org/10.1007/s12325–020–01524–6. PMID: 33123967.
23. Werion A., Belkhir L., Perrot M., Schmit G., Aydin S., Chen Z., et al. SARS-CoV-2 causes a specific dysfunction of the kidney proximal tubule. Kidney Int. 2020; 98 (5): 1296–1307. https://doi.org/10.1016/j.kint.2020.07.019. PMID: 32791255.
24. Diao B., Wang C., Wang R., Feng Z., Zhang J., Yanget H., et al. Human kidney is a target for novel severe acute respiratory syndrome coronavirus 2 infection. Nat Commun. 2021; 12 (1): 2506. https://doi.org/10.1038/s41467–021–22781–1. PMID: 33947851.
Review
For citations:
Petrikov S.S., Ivannikov A.A., Tarzimanova A.I., Bulanov A.Yu., Mikhaylov I.P., Dandanyan L.A., Alidzhanova H.G. Predictors of thrombotic events in patients with post-COVID condition. Medical alphabet. 2022;(17):7-14. (In Russ.) https://doi.org/10.33667/2078-5631-2022-17-7-14
Views:
408
Email this article 